BioSpace News Archive

Drug Development

Embattled Researchers See Path Forward for Anti-CD47 Cancer Drugs

With recent high-profile failures, experts say safety concerns and a lack of diversification are hindering the field—but still hold out hope for an approval.

October 26, 2023
·
6 min read
·
Maddie Bender
Business

BMS Pushes Back Target Sales for New Drugs as Q3 Revenue Declines

The company on Thursday said it now expects more than $10 billion in new product sales in 2026, despite previously forecasting $10 billion to $13 billion in 2025.

October 26, 2023
·
2 min read
·
Matt Olszewski
Drug Development

Alnylam Publishes Phase III ATTR-CM Data for Patisiran After FDA Rejection

Following the regulator’s denial of patisiran’s label expansion, Alnylam has published late-stage data for the RNAi therapeutic in The New England Journal of Medicine demonstrating its efficacy in ATTR-cardiomyopathy.

October 26, 2023
·
2 min read
·
Tristan Manalac
Business

Takeda Reports $770M Write-Down, Cuts Profit Forecast by 71% for FY2023

Attributing losses to exchange rate and pipeline impairment losses, the Japanese biopharma dropped its reported net profit forecast of 142 billion yen ($945.1 million) to 93 billion yen ($618.8 million).

October 26, 2023
·
2 min read
·
Kate Goodwin
Drug Development

Eisai, Biogen Build Case for Subcutaneous Leqembi for Alzheimer’s at CTAD

Subcutaneous injections of Eisai and Biogen’s Leqembi led to numerically greater amyloid removal than the intravenous version of the Alzheimer’s disease therapy, though risks of brain swelling and bleeding remained.

October 26, 2023
·
2 min read
·
Tristan Manalac
Drug Development

BioXcel Alzheimer’s Trial Shows No Signs of Misconduct, Finds Independent Audit

A third-party audit found no integrity and reliability problems with data from BioXcel Therapeutics’ Phase III trial. The company intends to file a supplemental New Drug Application for its candidate BXCL501.

October 26, 2023
·
2 min read
·
Tristan Manalac
Genetown

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Ipsen, a global specialty-driven biopharmaceutical company, presents its sales performance for the year to date and the third quarter of 2023.

October 26, 2023
·
9 min read
Business

Pharming Group reports third quarter 2023 financial results

Pharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2023.

October 26, 2023
·
26 min read
Genetown

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Takeda announced financial results for the first half of fiscal year 2023, updating reported and Core forecasts and reconfirming Management Guidance for Core change at CER.

October 26, 2023
·
11 min read
Business

Hansa Biopharma Interim Report January-September 2023

Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to September 2023.

October 26, 2023
·
9 min read